Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure

• Published in: Translational oncology Vol. 11; no. 5; pp. 1155 - 1159
• Main Authors: Cui, ChuanLiang, Zhou, Li, Lian, Bin, Si, Lu, Sheng, XiNan, Chi, ZhiHong, Kong, Yan, Wang, Xuan, Tang, BiXia, Mao, LiLi, Li, SiMing, Dai, Jie, Yan, XieQiao, Bai, Xue, Guo, Jun
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2018; Elsevier
• ISSN: 1936-5233
• DOI: 10.1016/j.tranon.2018.07.009

OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients. Novel treatment strategies are demanded after conventional treatment failure. This was a prospective, single-arm, and single-center dose escalation study to investigate the safety and preliminary efficacy of apatinib combined with temozolomide in heavily treated advanced melanoma patients. METHODS: Patients were sequentially admitted to four dose-escalating groups of apatinib and temozolomide (three cases in each group) using a traditional 3 + 3 dose escalation design method. RESULTS: Twelve patients were enrolled between December 2016 and August 2017. Most patients with an acral or mucosal primary origin progressed after immunotherapy or targeted therapy. Dose escalation had been completed without dose-limiting toxicity. Common adverse events included hypertension, hand-foot syndrome, proteinuria, neutropenia, nausea, and fatigue. All adverse events were grade 1 or 2, while the maximum tolerated dose was not reached. Up to January 2018, 1 patient achieved partial response, 9 experienced stable disease, and 2 exhibited progressive disease. The objective response rate and disease control rate were 8.3% and 83%, respectively. CONCLUSIONS: In conclusion, apatinib combined with temozolomide was well tolerated and has demonstrated efficacy in advanced melanoma patients.